– The study was published online by the Korean Society of Veterinary Science on. released May 27th
– The study investigated the therapeutic effect and safety after oral administration to companion dogs that cannot adequately control blood sugar levels with insulin
Seoul, South Korea, June 1, 2021 / PRNewswire / – Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effects of enavogliflozin, originally developed as a human type II diabetes treatment, on the treatment of canine diabetes have been published online by the Korean Society of Veterinary Science were May 27th.
This study was carried out by five institutions, including the research team of Prof. Hwa-Young Yoon at the College of Veterinary Medicine of Seoul National University to evaluate the effect of the medicine on blood sugar control and safety in dogs who cannot adequately control blood sugar levels with an injection of insulin. Similar to Type I diabetes in humans, canine diabetes is caused by the pancreas not producing enough insulin, so the main treatment is to give insulin by injection every day.
In the study, researchers compared fructosamine, fasting glucose, and insulin dose changes in one group treated with insulin and enavogliflozin once daily for eight weeks and once every three days in the other group to assess and observe the effect on glucose control additionally weight and blood pressure. Fructosamine is the average blood sugar for two to three weeks, and diabetes is diagnosed when it rises above normal.
The results showed that fructosamine levels decreased by 20% in the once-daily group and by 15% in the once-every-three-day group, and a blood sugar lowering effect was confirmed to be statistically significant in both groups. The changes in insulin dose decreased by 25% in the once daily group and 15% in the once every three days group, and the statistical significance was confirmed in the once daily group.
The fasting glucose level decreased in both groups, but there was no statistically significant difference. The weight decreased by 5% in the once-daily group and 2% in the once-daily group, and the blood pressure decreased by 20 mmHg in the once-daily group, confirming statistical significance. In addition, treatment with enavogliflozin did not result in any serious adverse event such as diabetic ketoacidosis or severe hypoglycaemia.
“With this study, we have confirmed the effects of enavogliflozin given with insulin in the treatment of diabetes in pets, including dogs,” said Ju-Hyun An, Doctor at the College of Veterinary Medicine of Seoul National University at its presentation. “When administered once a day, it showed a better therapeutic effect. Since no serious side effects were found in either group, safety was also confirmed.”
CEO of Daewoong Pharmaceutical Sengho Jeon said, “With this investigator-initiated study, we have for the first time confirmed the possibility that enavogliflozin can help pets control blood sugar levels. Since there are no oral medications for canine diabetes for pets other than insulin injections, a drug has been developed for animals is expected to become a new treatment option. “
As of 2019, the number of households keeping pets is 5.91 million (26.4%), and the Korean pet market is expected to grow. to grow KRW 6 trillion by 2027. While diabetes affects 1 in 300 dogs and 1 in 200 cats, there is no oral drug available to treat diabetes in animals, and most are known to be treated with insulin injections.
Enavogliflozin is currently being developed by Daewoong Pharmaceutical and is an oral treatment for type II diabetes. Clinical studies are being conducted on the administration of enavogliflozin alone with metformin in a triple therapy with metformin and a DPP-4 inhibitor. The company is developing enavogliflozin as a best-in-class drug and aims to launch it in Korea by 2023.
For more information please contact:
Cheolheon Park (chpark049@daewoong.co.kr), Daewoong PR Manager
similar links
http://www.daewoong.com/
SOURCE Daewoong Pharmaceutical Co., Ltd
